GGrantIndex
← Leaderboards

Elisabeth D Martinez

Ut Southwestern Medical Center

$4,685,595
Attributed
$5,631,546
Total exposure
9
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $661.7K · FY200625
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$5,631,546 · 9

By mechanism

R01$1,797,544 · 1
R21$1,499,943 · 4
R33$1,454,652 · 1
K22$458,186 · 1
R03$309,819 · 1
P50$111,402 · 1

Top collaborators

Most similar at Ut Southwestern Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Epigenetic Process

Research focus

Epigenetic ProcessEnzymesCellsIn VivoCell LineGenesHistonesGrowthMalignant NeoplasmsTumorPathway InteractionsEventGene ExpressionCell DeathGenomicsPharmaceutical PreparationsChromatinMammalian CellMalignant Neoplasm Of LungCancer CellFoundationsBaseAffectMolecular

Grant awards (26)

Jumonji enzyme action in hepatocellular carcinoma onset$230,010
R21 · FY2025 · CA · contact PI
Jumonji KDM4A drives targetable oncogenic programs in small cell lung cancer$191,675
R21 · FY2025 · CA · contact PI
Career Enhancement Program$111,402
P50 · FY2025 · CA · contact PI
Jumonji enzyme action in hepatocellular carcinoma onset$191,675
R21 · FY2024 · CA · contact PI
Post-translational modifications control JARID enzyme activity during DNA damage$82,000
R03 · FY2024 · CA · contact PI
Post-translational modifications control JARID enzyme activity during DNA damage$74,864
R03 · FY2024 · CA · contact PI
Post-translational modifications control JARID enzyme activity during DNA damage$82,000
R03 · FY2023 · CA · contact PI
Post-translational modifications control JARID enzyme activity during DNA damage$70,955
R03 · FY2023 · CA · contact PI
Epigenetic reprogramming of the malaria parasite$204,583
R21 · FY2021 · AI · contact PI
Epigenetic reprogramming of the malaria parasite$244,750
R21 · FY2020 · AI · contact PI
Novel small molecules to reactivate latent HIV and sensitize to anti-viral therapies$484,884
R33 · FY2018 · AI
Novel small molecules to reactivate latent HIV and sensitize to anti-viral therapies$484,884
R33 · FY2017 · AI
Novel small molecules to reactivate latent HIV and sensitize to anti-viral therapies$484,884
R33 · FY2016 · AI
Novell small molecules to reactivate latent HIV and sensitize to anti-viral therapies$218,625
R21 · FY2015 · AI
Characterization of the biological activities of novel epigenetic modulators$310,426
R01 · FY2014 · CA · contact PI
Novell small molecules to reactivate latent HIV and sensitize to anti-viral therapies$218,625
R21 · FY2014 · AI
Characterization of the biological activities of novel epigenetic modulators$132,638
R01 · FY2014 · CA · contact PI
Characterization of the biological activities of novel epigenetic modulators$300,826
R01 · FY2013 · CA · contact PI
Characterization of the biological activities of novel epigenetic modulators$86,389
R01 · FY2013 · CA · contact PI
Characterization of the biological activities of novel epigenetic modulators$319,356
R01 · FY2012 · CA · contact PI
Characterization of the biological activities of novel epigenetic modulators$319,021
R01 · FY2011 · CA · contact PI
Characterization of the biological activities of novel epigenetic modulators$328,888
R01 · FY2010 · CA · contact PI
Characterization of small molecule inhibitors of HDACs and DNMTs$60,500
K22 · FY2009 · CA · contact PI
Characterization of small molecule inhibitors of HDACs and DNMTs$136,596
K22 · FY2008 · CA · contact PI
Characterization of small molecule inhibitors of HDACs and DNMTs$134,190
K22 · FY2007 · CA · contact PI
Characterization of small molecule inhibitors of HDACs and DNMTs$126,900
K22 · FY2006 · CA · contact PI